

Supplementary Information

Figure S1. Percentage of SARS-CoV-2 variants circulating in Thailand between 21 April 2021 and 20 September 2021.




Table S1. Binding antibody levels including total anti-RBD Ig and anti-RBD IgG. Neutralizing activities of sera from the three groups were measured via surrogate virus neutralization tests.

	CV+CV (<i>n</i> = 170)	CV+CV+AZ (<i>n</i> = 210)	CV+CV+INF (<i>n</i> = 77)
Anti-RBD-Ig <i>n</i>	170	210	77
GMT (95% CI)	98 (83–116)	7947 (7277–8679)	19,698 (15335–25,302)
Anti-RBD IgG <i>n</i>	170	210	77
GMT (95% CI)	128 (114–144)	1492 (1367–1629)	3946 (3135–4965)
sVNT-wuhan <i>n</i>	36	36	77
Median (IQR)	66.6 (48.9–79.4)	97.7 (97.0–97.8)	97.5 (97.3–97.6)

sVNT-B.1.1.7 (alpha) <i>n</i> Median (IQR)	36 42.1 (29.0–58.3)	36 97.2 (94.7–97.7)	78 97.7 (97.3–98.0)
sVNT-B.1.351 (beta) <i>n</i> Median (IQR)	36 34.8 (20.5–47.3)	36 92.9 (86.8–94.8)	78 95.6 (93.9–96.2)
sVNT-B.1.617.2 (delta) <i>n</i> Median (IQR)	36 48.9 (36.1–63.4)	36 97.2 (95.6–97.9)	78 97.9 (97.7–98.0)

CI, confidence interval; CV+CV, fully vaccinated with two doses of CoronaVac; CV+CV+AZ, fully vaccinated with two doses of CoronaVac then administered a third vaccination with AZD1222; CV+CV+INF, fully vaccinated with two doses of CoronaVac followed by SARS-CoV-2 breakthrough infection; GMT, geometric mean titre; IQR, interquartile range; RBD, receptor-binding domain